Add to ORKGMany countries, including Australia, regulate the price consumers pay for pharmaceuticals. In this paper, the Australian Pharmaceutical Benefits Scheme (PBS) is modelled as a multi-stage game played between the regulator and pharmaceutical firms. Conditions are derived under which vertically differentiated firms are regulated and a number of issues are discussed. These include efficiency, regulated firm profitability, leakage, and price discrimination. An extension examines the introduction of new drugs and concludes that if all the benefits of a new drug are to be realised, then existing agreements and transfers (per-unit subsidies) need to be renegotiated
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
Universal access to affordable medicines, which are safe, efficacious and of high quality, and which...
With the third round of trade negotiations currently underway, this paper explores possible conseque...
Australia pays less than other developed nations for her pharmaceuticals, about 45% as much as the U...
The pharmaceutical subsidy scheme in Australia works in the public interest by keeping prices low wh...
This paper describes developments in Australia’s regulation of prescription drug marketing and promo...
In this paper, we analyse the market for drugs in health care markets where third payers (an insuran...
The paper will describe and attempt to assess some of the evidence in relation to six hypotheses. It...
The paper will describe and attempt to assess some of the evidence in relation to six hypotheses. It...
The issues at stake for determining the price of a drug are related to finding an "equitable" trade-...
This paper considers the likely impact of reforms sought by the US pharmaceutical companies on the P...
It is commonly believed that dispensed prices of medicines in Australia are substantially lower than...
Drug price regulation is acquiring increasing significance in the investment choices of the pharmace...
The Pharmaceutical Management Agency of New Zealand (PHARMAC) and the Pharmaceutical Benefits Scheme...
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
Universal access to affordable medicines, which are safe, efficacious and of high quality, and which...
With the third round of trade negotiations currently underway, this paper explores possible conseque...
Australia pays less than other developed nations for her pharmaceuticals, about 45% as much as the U...
The pharmaceutical subsidy scheme in Australia works in the public interest by keeping prices low wh...
This paper describes developments in Australia’s regulation of prescription drug marketing and promo...
In this paper, we analyse the market for drugs in health care markets where third payers (an insuran...
The paper will describe and attempt to assess some of the evidence in relation to six hypotheses. It...
The paper will describe and attempt to assess some of the evidence in relation to six hypotheses. It...
The issues at stake for determining the price of a drug are related to finding an "equitable" trade-...
This paper considers the likely impact of reforms sought by the US pharmaceutical companies on the P...
It is commonly believed that dispensed prices of medicines in Australia are substantially lower than...
Drug price regulation is acquiring increasing significance in the investment choices of the pharmace...
The Pharmaceutical Management Agency of New Zealand (PHARMAC) and the Pharmaceutical Benefits Scheme...
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
This paper reports on some of the findings to date of the Centre’s pharmaceuticals research program,...
Universal access to affordable medicines, which are safe, efficacious and of high quality, and which...